Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 13 studies | 26% ± 10% | |
platelet | 11 studies | 77% ± 21% | |
smooth muscle cell | 9 studies | 26% ± 14% | |
glutamatergic neuron | 9 studies | 69% ± 20% | |
type II pneumocyte | 8 studies | 32% ± 12% | |
pericyte | 8 studies | 24% ± 6% | |
megakaryocyte | 6 studies | 79% ± 16% | |
oligodendrocyte | 5 studies | 21% ± 5% | |
endothelial cell | 4 studies | 38% ± 22% | |
GABAergic neuron | 4 studies | 19% ± 3% | |
non-classical monocyte | 3 studies | 30% ± 5% | |
astrocyte | 3 studies | 20% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 8 studies | 42% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 74% | 43132.63 | 1950 / 2642 | 96% | 373.27 | 678 / 705 |
lung | 77% | 2842.73 | 443 / 578 | 82% | 45.66 | 945 / 1155 |
kidney | 34% | 813.43 | 30 / 89 | 68% | 18.15 | 615 / 901 |
ureter | 0% | 0 | 0 / 0 | 100% | 33.35 | 1 / 1 |
thymus | 3% | 54.44 | 21 / 653 | 93% | 34.26 | 560 / 605 |
ovary | 8% | 136.27 | 15 / 180 | 85% | 39.85 | 365 / 430 |
uterus | 9% | 148.35 | 15 / 170 | 79% | 21.46 | 361 / 459 |
pancreas | 0% | 0 | 0 / 328 | 83% | 14.59 | 148 / 178 |
lymph node | 0% | 0 | 0 / 0 | 83% | 22.81 | 24 / 29 |
bladder | 5% | 75.90 | 1 / 21 | 76% | 18.92 | 384 / 504 |
peripheral blood | 80% | 9475.54 | 747 / 929 | 0% | 0 | 0 / 0 |
spleen | 78% | 2552.54 | 187 / 241 | 0% | 0 | 0 / 0 |
skin | 4% | 74.97 | 77 / 1809 | 71% | 16.33 | 334 / 472 |
intestine | 1% | 8.85 | 5 / 966 | 74% | 11.22 | 388 / 527 |
stomach | 0% | 5.30 | 1 / 359 | 72% | 11.28 | 207 / 286 |
adrenal gland | 0% | 0 | 0 / 258 | 71% | 133.30 | 163 / 230 |
blood vessel | 68% | 2367.70 | 910 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 0% | 6.57 | 6 / 1445 | 58% | 8.37 | 106 / 183 |
breast | 3% | 52.78 | 12 / 459 | 54% | 7.42 | 609 / 1118 |
tonsil | 0% | 0 | 0 / 0 | 40% | 6.63 | 18 / 45 |
liver | 0% | 0 | 0 / 226 | 38% | 5.54 | 153 / 406 |
prostate | 0% | 0 | 0 / 245 | 36% | 4.16 | 180 / 502 |
eye | 0% | 0 | 0 / 0 | 13% | 1.75 | 10 / 80 |
adipose | 7% | 127.64 | 85 / 1204 | 0% | 0 | 0 / 0 |
heart | 4% | 71.98 | 35 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 2.43 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0007399 | Biological process | nervous system development |
GO_0005829 | Cellular component | cytosol |
GO_0005516 | Molecular function | calmodulin binding |
Gene name | NRGN |
Protein name | Neurogranin (Ng) (RC3) [Cleaved into: NEUG(55-78)] |
Synonyms | |
Description | FUNCTION: Acts as a 'third messenger' substrate of protein kinase C-mediated molecular cascades during synaptic development and remodeling. Binds to calmodulin in the absence of calcium (By similarity). . |
Accessions | ENST00000412681.2 ENST00000284292.11 Q92686 |